Hepatitis C: Thyroid dysfunction in patients with hepatitis C on IFN-α therapy

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 11, 2009, Pages 633-635

  Antonelli, Alessandro ^a   Ferri, Clodoveo ^b   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; RIBAVIRIN; THYROID PEROXIDASE; THYROID PEROXIDASE ANTIBODY;

ARTICLE; AUTOIMMUNE PRIMARY HYPOTHYROIDISM; AUTOIMMUNE THYROIDITIS; CYTOKINE PRODUCTION; DESTRUCTIVE THYROIDITIS; DISEASE ASSOCIATION; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; FOOD INTAKE; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; HYPOTHYROIDISM; INCIDENCE; IODINE INTAKE; LONG TERM CARE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THYROID DISEASE; THYROIDITIS; TREATMENT DURATION;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; PREVALENCE; THYROIDITIS, AUTOIMMUNE;

EID: 71049138502     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.168     Document Type: Article

References (12)

1. Prummel, M. F. & Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 13, 547-551 (2003).
2. Tomer, Y., Blackard, J. T. & Akeno, N. Interferon alpha treatment and thyroid dysfunction. Endocrinol. Metab. Clin. North Am. 36, 1051-1066 (2007).
3. Fernandez-Soto, L. et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch. Intern. Med. 158, 1445-1448 (1998).
4. Antonelli, A. et al. Thyroid disorders in chronic hepatitis C. Am. J. Med. 117, 10-13 (2004).
5. Antonelli, A. et al. Thyroid disorders in hepatitis C virus chronic infection. Thyroid 16, 563-572 (2006).
6. Giordano, T. P. et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 297, 2010-2017 (2007).
7. Vezali, E., Elefsiniotis, I., Mihas, C., Konstantinou, E. & Saroglou, G. Thyroid dysfunction in patients with chronic hepatitis C: Virus- or therapy-related? J. Gastroenterol. Hepatol. 24, 1024-1029 (2009).
8. Jamil, K. M. et al. Interferon-induced thyroid dysfunction in chronic hepatitis C. J. Gastroenterol. Hepatol. 24, 1017-1023 (2009).
9. Tran, H. A., Attia, J. R., Jones, T. L. & Batey, R. G. Pegylated interferon-a2b incombination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-a2b in a hepatitis C population: Meta-analysis. J. Gastroenterol. Hepatol. 22, 472-476 (2007).
10. Hultgren, C., Milich, D. R., Weiland, O. & Sallberg, M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 79, 2381-2391 (1998).
11. Yalowitz, J. A. & Jayaram, H. N. Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res. 20, 2329-2338 (2000).
12. Antonelli, A. et al. Endocrine manifestations of hepatitis C virus infection. Nat. Clin. Pract. Endocrinol. Metab. 5, 26-34 (2009).